ALT
Altimmune, Inc.
Key Financials
Net Income
$-88093000
↑ 7.3%
Revenue
$41000
↑ 105.0%
Operating Income
$-94489000
↑ 8.4%
EPS (Diluted)
$-1.00
↑ 25.4%
Total Liabilities
$55.0M
↑ 248.4%
Shareholders' Equity
$224.9M
↑ 82.1%
Total Assets
$279.9M
↑ 100.9%
Cash & Equivalents
$43.8M
↑ 18.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/16/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| S-8 | 5/13/2026 | View on SEC |
| 10-Q | 5/13/2026 | View on SEC |
| 8-K | 5/13/2026 | View on SEC |
| SCHEDULE 13G | 5/12/2026 | View on SEC |
| SCHEDULE 13G | 5/1/2026 | View on SEC |
| SCHEDULE 13G | 5/1/2026 | View on SEC |
| 4 | 5/1/2026 | View on SEC |
| 4 | 5/1/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ALT |
| Company Name | Altimmune, Inc. |
| CIK | 1326190 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 2406541450 |